Ignoring debt funds amid equity rally is a portfolio mistake...
15 Apr 2026
iSERA Lifesciences Limited has announced that its Board of Directors will convene on Monday, April 20, 2026, to deliberate on significant corporate matters, including a proposed preferential issue of equity shares. The company, formerly known as Covid Technologies Limited, has formally notified BSE Limited about this scheduled meeting in accordance with regulatory requirements.
Meeting Agenda and Purpose
The primary focus of the Board meeting will be to consider and approve the preferential issue of equity shares on a private placement basis. This corporate action represents a significant capital-raising initiative for the pharmaceutical company. The meeting will also address other business matters, though specific details of additional agenda items have not been disclosed.
Regulatory Compliance Details
Parameter: Details Meeting Date: Monday, April 20, 2026 Regulation: SEBI (LODR) Regulations, 2015 - 29(1)(d) Notification Date: April 15, 2026 Exchange Informed: BSE Limited Scrip Code: 534920 ISIN: INE899M01020
The notification was submitted pursuant to Regulation 29(1)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates prior intimation of Board meetings for specific corporate actions.
Company Information
iSERA Lifesciences Limited operates from its registered office located at Office No. A1-1202, 12th Floor, Boulevard Tower, Phase-2, CTS No. 11, Sadhu Vaswani Chowk, Camp, Pune – 411001. The company maintains its corporate identity under CIN: L72200PN1993PLC252720 and trades on BSE with scrip code 534920.
Authorization and Documentation
The formal communication to BSE was digitally signed by Deepakshi, Company Secretary & Compliance Officer (Membership No.: A76335), on April 15, 2026. The digital signature was authenticated at 17:41:26 +05'30', ensuring proper documentation and compliance with electronic filing requirements.
The preferential issue, if approved, will enable the company to raise capital through private placement, providing strategic flexibility for business expansion and operational requirements. Shareholders and market participants will await the Board's decision following the April 20, 2026 meeting.
Covidh Technologies Limited has officially been renamed to iSERA Lifesciences Limited following approval from the Ministry of Corporate Affairs (MCA) with effect from April 10, 2026. The company informed BSE Limited about the name change approval under Regulation 30 of SEBI Listing Regulations.
MCA Approval and Certificate Issuance
The Registrar of Companies, Pune, Ministry of Corporate Affairs approved the name change from "Covidh Technologies Limited" to "iSERA Lifesciences Limited" on April 10, 2026. A fresh Certificate of Incorporation was issued by the Central Processing Centre, signed digitally by Assistant Registrar Prerna Panwar.
Parameter: Details Effective Date: April 10, 2026 New Company Name: iSERA Lifesciences Limited Former Name: Covidh Technologies Limited CIN: L72200PN1993PLC252720 Scrip Code: 534920 ISIN: INE899M01020
Corporate Timeline and Approvals
The name change process involved multiple regulatory steps. The Board of Directors initially approved the name change proposal on March 10, 2026, followed by an Extraordinary General Meeting notice. Subsequently, on April 02, 2026, shareholders passed a Special Resolution approving the company name change during the 1st Extra-Ordinary General Meeting.
Company Secretary and Compliance Officer Deepakshi (Membership No.: A76335) submitted the intimation to BSE Limited's Department of Corporate Services on April 10, 2026. The submission included the fresh Certificate of Incorporation issued by MCA as supporting documentation.
Memorandum and Articles Amendment
The company's Memorandum of Association and Articles of Association have been altered to reflect the name change. According to MCA regulations, the company must display its former name "Covidh Technologies Limited" alongside the new name "iSERA Lifesciences Limited" for a period of two years at all places where the company name is required to be displayed under Section 12 of the Companies Act.
Updated Corporate Information
The company operates from Office No. A1-1202, 12th Floor, Boulevard Tower, Phase-2, CTS No. 11, Sadhu Vaswani Chowk, Camp, Pune – 411001. The original incorporation was under the name "Aarya Consultants Private Limited" before the current transformation to iSERA Lifesciences Limited.
Previous Compliance Activities
Prior to the name change approval, the company had submitted its quarterly compliance certificate to BSE Limited for Q4FY26 ended March 31, 2026. The certificate, issued by Registrar and Share Transfer Agent Skyline Financial Services Private Limited, confirmed that no physical share certificates were received for dematerialization during the quarter, maintaining compliance with SEBI Regulation 74(5).
We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.
Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.
